Captor Therapeutics S.A. Cash Flow-to-Debt Ratio
Captor Therapeutics S.A. cash flow-to-debt ratio. Captor Therapeutics S.A. (CTX) has a Cash Flow-to-Debt Ratio of -1.02x as of September 2025, meaning its operating cash flow of zł-11.51 Million could theoretically repay -1% of its total liabilities (zł11.27 Million) in one year. See financial flexibility index of Captor Therapeutics S.A. to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Captor Therapeutics S.A. (2017–2024)
Cash flow-to-debt ratio of Captor Therapeutics S.A. from 2017 to 2024. Historical debt coverage capacity for Captor Therapeutics S.A. across 8 annual periods. Check total reinvestment intensity of Captor Therapeutics S.A. to assess the company's total reinvestment commitment from operating cash flow.
Captor Therapeutics S.A. Cash Flow-to-Debt Ratio by Year (2017–2024)
Captor Therapeutics S.A. cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Captor Therapeutics S.A.. For the full cash flow conversion analysis, see how efficiently does Captor Therapeutics S.A. generate cash.
| Year | CF-to-Debt Ratio | Operating CF (PLN) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.38x | zł-31.88 Million | zł23.02 Million | ▲ +25.5% |
| 2023 | -1.86x | zł-52.20 Million | zł28.07 Million | ▼ -35.1% |
| 2022 | -1.38x | zł-22.95 Million | zł16.68 Million | ▲ +6.5% |
| 2021 | -1.47x | zł-28.47 Million | zł19.34 Million | ▼ -6527.0% |
| 2020 | -0.02x | zł-595.00K | zł26.78 Million | ▼ -110.6% |
| 2019 | 0.21x | zł4.39 Million | zł21.02 Million | ▲ +243.5% |
| 2018 | -0.15x | zł-2.13 Million | zł14.63 Million | ▼ -134.6% |
| 2017 | 0.42x | zł2.10 Million | zł4.98 Million | — |